Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Retained Earnings (2020 - 2026)

InMed Pharmaceuticals has reported Retained Earnings over the past 5 years, most recently at -$121.0 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 94207.46% year-over-year to -$121.0 million; the TTM value through Dec 2025 reached -$121.0 million, down 94207.46%, while the annual FY2025 figure was $128569.0, 100.12% up from the prior year.
  • Retained Earnings for Q4 2025 was -$121.0 million at InMed Pharmaceuticals, down from -$119.0 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $128569.0 in Q2 2021 and troughed at -$121.0 million in Q4 2025.
  • A 5-year average of -$65.8 million and a median of -$97.0 million in 2022 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: soared 100.12% in 2024 and later plummeted 94207.46% in 2025.
  • Year by year, Retained Earnings stood at $128569.0 in 2021, then changed by 0.0% to $128569.0 in 2022, then tumbled by 82079.33% to -$105.4 million in 2023, then soared by 100.12% to $128569.0 in 2024, then plummeted by 94207.46% to -$121.0 million in 2025.
  • Business Quant data shows Retained Earnings for INM at -$121.0 million in Q4 2025, -$119.0 million in Q3 2025, and $128569.0 in Q2 2025.